FDA Approved: JAKAFI — Original Application (Incyte Corporation)

View source ↗

Summary

The FDA granted original approval for JAKAFI (ruxolitinib) by Incyte Corporation, marking the first approval of this drug for the treatment of myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

ORIG AP for JAKAFI (RUXOLITINIB)